GKV Capital Management Co. Inc. Invests $504,000 in Stryker Co. (NYSE:SYK)

GKV Capital Management Co. Inc. purchased a new position in shares of Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,400 shares of the medical technology company's stock, valued at approximately $504,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the 4th quarter valued at about $25,000. Rakuten Securities Inc. boosted its holdings in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Stryker during the 4th quarter worth $30,000. BankPlus Trust Department purchased a new position in shares of Stryker in the 4th quarter worth $33,000. Finally, Activest Wealth Management acquired a new position in Stryker in the fourth quarter valued at $36,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SYK shares. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, March 6th. Citigroup reiterated a "buy" rating and set a $450.00 price objective on shares of Stryker in a research note on Wednesday, February 26th. Argus set a $450.00 target price on shares of Stryker in a research note on Monday, February 3rd. JPMorgan Chase & Co. lifted their target price on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group boosted their price objective on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $423.53.

Stryker Stock Up 2.6 %

Stryker stock traded up $8.67 during mid-day trading on Tuesday, reaching $348.26. The company's stock had a trading volume of 395,267 shares, compared to its average volume of 1,353,834. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The business's 50 day simple moving average is $370.04 and its 200 day simple moving average is $373.23. The company has a market capitalization of $132.93 billion, a price-to-earnings ratio of 44.88, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the company posted $3.46 EPS. As a group, research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.96%. Stryker's dividend payout ratio (DPR) is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.